Found: 28
Select item for more details and to access through your institution.
Serotonin Antagonists: A New Class of Antiemetic Agents.
- Published in:
- JNCI: Journal of the National Cancer Institute, 1991, v. 83, n. 9, p. 613
- By:
- Publication type:
- Article
Pneumocystis carinii Pneumonia Complicating Somatostatin Therapy of Cushing's Syndrome in a Patient with Metastatic Pancreatic Islet Cell Carcinoma and Zollinger-Ellison Syndrome.
- Published in:
- American Journal of Gastroenterology (Springer Nature), 1991, v. 86, n. 4, p. 512
- By:
- Publication type:
- Article
Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents—updated MASCC/ESMO consensus recommendation.
- Published in:
- Supportive Care in Cancer, 2024, v. 32, n. 1, p. 1, doi. 10.1007/s00520-023-08220-5
- By:
- Publication type:
- Article
2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents.
- Published in:
- Supportive Care in Cancer, 2024, v. 32, n. 1, p. 1, doi. 10.1007/s00520-023-08222-3
- By:
- Publication type:
- Article
Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic.
- Published in:
- 2018
- By:
- Publication type:
- journal article
2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy.
- Published in:
- 2017
- By:
- Publication type:
- journal article
2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Erratum to: 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy.
- Published in:
- 2017
- By:
- Publication type:
- journal article
2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings-a meta-analysis.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting.
- Published in:
- 2015
- By:
- Publication type:
- journal article
The increasing frequency of adenocarcinoma of the esophagus.
- Published in:
- 1989
- By:
- Publication type:
- journal article
Treatment of advanced non-small cell lung cancer with cisplatin, 5-fluorouracil, and mitomycin C.
- Published in:
- 1988
- By:
- Publication type:
- journal article
Massive Retroperitoneal Adrenal Hemorrhage Secondary to Lung Cancer Metastasis Treated by Adrenal Artery Embolization.
- Published in:
- Clinical Lung Cancer, 2009, v. 10, n. 5, p. E1, doi. 10.3816/CLC.2009.n.053
- By:
- Publication type:
- Article
Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy.
- Published in:
- Cancer (0008543X), 1997, v. 79, n. 6, p. 1216, doi. 10.1002/(SICI)1097-0142(19970315)79:6<1216::AID-CNCR22>3.0.CO;2-1
- By:
- Publication type:
- Article
Treatment of advanced non-small cell lung cancer with very high-dose cisplatin combined with etoposide and mitomycin C.
- Published in:
- 1993
- By:
- Publication type:
- journal article
Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy.
- Published in:
- Cancer (0008543X), 2005, v. 104, n. 7, p. 1548, doi. 10.1002/cncr.21343
- By:
- Publication type:
- Article
A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies (Performed on behalf of the Darbepoetin Alfa 20010102 Study Group. The authors thank the study coordinators and patients at each of the participating centers. Janis Schaap, M.A., assisted in the writing of the article.) Additional members of the Darbepoetin Alfa 20010102 Study Group include the following: Luigi F. Bertoli, M.D. (Clinical Research Consultants, Inc., Hoover, Alabama); John T. Cole, M.D. (Ochsner Clinic Foundation, New Orleans, Louisiana); George Demetri, M.D. (Dana-Farber Cancer Institute, Boston, Massachusetts); Emmanuel Dessypris, M.D. (Hunter Holmes McGuire Department of Veterans Affairs Medical Center, Richmond, Virginia); Tracy Dobbs, M.D. (Baptist Hospital of East Tennessee, Knoxville, Tennessee); Peter Ei)
- Published in:
- Cancer (0008543X), 2004, v. 100, n. 4, p. 859, doi. 10.1002/cncr.11954
- By:
- Publication type:
- Article
Establishing the dose of the oral NK<sub>1</sub> antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
- Published in:
- Cancer (0008543X), 2003, v. 97, n. 9, p. 2290, doi. 10.1002/cncr.11320
- By:
- Publication type:
- Article
Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).
- Published in:
- 2011
- By:
- Publication type:
- journal article
Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
- Published in:
- Oncologist, 2016, v. 21, n. 4, p. 494, doi. 10.1634/theoncologist.2015-0301
- By:
- Publication type:
- Article
Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC.
- Published in:
- PLoS ONE, 2018, v. 13, n. 11, p. 1, doi. 10.1371/journal.pone.0208097
- By:
- Publication type:
- Article